Literature DB >> 19719454

Current perspectives in prostate cancer vaccines.

Philip M Arlen1, James L Gulley.   

Abstract

The use of vaccines as a potential therapeutic modality for the treatment of cancer has been extensively studied. Recent advances include identification and characterization of tumor-associated antigens, novel vaccine delivery systems, and the combination of vaccines with immune stimulants and other therapeutic modalities. Immunotherapy as a modality for treatment of prostate cancer has received significant attention. There are several characteristics of prostate cancer that make it an ideal target for immunotherapy. Prostate cancer's relative indolence allows sufficient time to generate immune responses, which may take weeks or months to mount. In addition, prostate cancer-associated antigens direct the immune response to prostate cancer cells, thus sparing normal vital tissue. This review focuses on promising new vaccines and novel perspectives in the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719454      PMCID: PMC3471219          DOI: 10.2174/187152009789735062

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  64 in total

Review 1.  T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles.

Authors:  A G Wingren; E Parra; M Varga; T Kalland; H O Sjögren; G Hedlund; M Dohlsten
Journal:  Crit Rev Immunol       Date:  1995       Impact factor: 2.214

2.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

3.  Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide.

Authors:  Yasuhide Motoyoshi; Kazuhisa Kaminoda; Ohki Saitoh; Keisuke Hamasaki; Kazuhiko Nakao; Nobuko Ishii; Yuji Nagayama; Katsumi Eguchi
Journal:  Oncol Rep       Date:  2006-07       Impact factor: 3.906

4.  Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer.

Authors:  Hiromichi Kawaida; Koji Kono; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Akishi Ooi; Hideki Fujii
Journal:  J Surg Res       Date:  2005-03       Impact factor: 2.192

5.  Selective induction of high avidity CTL by altering the balance of signals from APC.

Authors:  SangKon Oh; James W Hodge; Jeffrey D Ahlers; Donald S Burke; Jeffrey Schlom; Jay A Berzofsky
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

6.  Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

Authors:  Michael A Morse; Amy C Hobeika; Takuya Osada; Delila Serra; Donna Niedzwiecki; H Kim Lyerly; Timothy M Clay
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

7.  IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

Authors:  Mary T Litzinger; Romaine Fernando; Tyler J Curiel; Douglas W Grosenbach; Jeffrey Schlom; Claudia Palena
Journal:  Blood       Date:  2007-07-06       Impact factor: 22.113

Review 8.  Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.

Authors:  James W Hodge; Chandan Guha; Jacques Neefjes; James L Gulley
Journal:  Oncology (Williston Park)       Date:  2008-08       Impact factor: 2.990

9.  Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.

Authors:  Mala Chakraborty; Scott I Abrams; Kevin Camphausen; Kebin Liu; Tamalee Scott; C Norman Coleman; James W Hodge
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

10.  Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.

Authors:  Eric J Small; Natalie Sacks; John Nemunaitis; Walter J Urba; Eugene Dula; Arthur S Centeno; William G Nelson; Dale Ando; Catherine Howard; Flavia Borellini; Minh Nguyen; Kristen Hege; Jonathan W Simons
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

View more
  1 in total

Review 1.  Recent developments in prostate cancer biomarker research: therapeutic implications.

Authors:  Sujitra Detchokul; Albert G Frauman
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.